Eng Hooi (Cheryl) Tan
BSc (Pharm), MPH, PhD
Senior Researcher in Pharmacoepidemiology
As a pharmacoepidemiologist, I apply methods to investigate the drug utilisation and comparative effectiveness and safety of medications using routinely collected healthcare data. I hope to support reliable evidence generation that translates into better patient care. In my work I contribute my expertise to multinational networks and consortiums such as OHDSI, EU-PEARL, OPTIMA, and DARWIN-EU.
I completed my PhD at the National University of Singapore (NUS). My thesis explored the detection of drug-induced liver injury in electronic medical records. I obtained my Master of Public Health (MPH) from the University of Sydney and graduated from NUS with a BSc (Pharmacy) as an ASEAN scholar.
My working experience includes practicing as a pharmacist in a tertiary hospital and an oncology centre. While working on my PhD, I was also a research associate managing a randomised controlled trial evaluating the use of SMS reminders to improve medication adherence in women with breast cancer.
I joined NDORMS in June 2020.
Recent publications
-
Incidence and survival of colorectal cancer in the United Kingdom from 2000-2021: a population-based cohort study.
Pedregal-Pascual P. et al, (2025), Am j gastroenterol
-
Treatment choice for adult patients with moderate-to-severe asthma – The TAILOR study
Jeannetot D. et al, (2025), Erj open research, 00869 - 2024
-
Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones.
Guo Y. et al, (2024), Pharmacoepidemiol drug saf, 33
-
Incidence, prevalence, and survival of prostate cancer in the UK
Tan EH. et al, (2024), Jama network open, 7
-
Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021.
Barclay NL. et al, (2024), Sci rep, 14